Armed dual CAR-T compositions and methods for cancer immunotherapy
AssigneeSimcere Innovation, Inc.
InventorsShengjun Ren, Hanan Dahche
Life of this patent
Estimating the term…
Abstract
The disclosure provides, in various embodiments, polynucleotides and vectors comprising sequences encoding a mono-specific or a bi-specific CAR that is capable of binding to a first TAA, or a T-cell engager that is capable of binding to CD3 and a second TAA, or a combination thereof. The disclosure also provides, in various embodiments, T lymphocytes comprising one or more of the polynucleotides or vectors; compositions (e.g., pharmaceutical compositions) and kits comprising one or more of the T lymphocytes; methods of treating a cancer in mammalian subject (e.g., a human), and methods of inducing T cell-mediated cytolysis of cancer cells (e.g., solid tumor cells).
Claims20
A method of treating cancer, comprising administering to a human patient in need thereof T lymphocytes comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, or SEQ ID NO:
- 38, wherein the cancer is glioblastoma (GBM), hepatocellular carcinoma (HCC), or a brain metastatic tumor.
A method of inducing T cell-mediated cytolysis of human cancer cells, comprising contacting the human cancer cells with T lymphocytes comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, or SEQ ID NO:
- 38, wherein the human cancer cells are cells of GBM, HCC, or a brain metastatic tumor.
Dependencies are inferred from the claim text.